Role of natural and adaptive immunity in renal cell carcinoma response to VEGFR-TKIs and mTOR inhibitor

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2772-2777

  Santoni, Matteo ^a   Berardi, Rossana ^a   Amantini, Consuelo ^b   Burattini, Luciano ^a   Santini, Daniele ^c   Santoni, Giorgio ^b   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^b UNIVERSITY OF CAMERINO   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

immune cells; immunotherapy; natural and adaptive immunity; renal cell carcinoma; targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR TYROSINE KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ADVANCED CANCER; BONE MARROW CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RESISTANCE; CARCINOGENESIS; CELLULAR IMMUNITY; DENDRITIC CELL; DISEASE ASSOCIATION; DRUG EFFECT; DRUG TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOPATHOLOGY; INNATE IMMUNITY; KIDNEY CARCINOMA; MACROPHAGE FUNCTION; METASTASIS; METASTASIS POTENTIAL; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SUPPRESSOR CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR INVASION;

IMMUNE CELLS; IMMUNOTHERAPY; NATURAL AND ADAPTIVE IMMUNITY; RENAL CELL CARCINOMA; TARGETED THERAPY;

ADAPTIVE IMMUNITY; ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; CELL MOVEMENT; CELL PROLIFERATION; DENDRITIC CELLS; HUMANS; IMMUNOSUPPRESSION; KIDNEY NEOPLASMS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; NEUTROPHIL ACTIVATION; NEUTROPHILS; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; T-LYMPHOCYTES; TOR SERINE-THREONINE KINASES;

EID: 84898011066     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28503     Document Type: Review

References (56)

1. Yang JC, Childs R,. Immunotherapy for renal cell cancer. J Clin Oncol 2006; 24: 5576-83.
2. Noessner E, Brech D, Mendler AN, et al. Intratumoral alterations of dendritic-cell differentiation and CD8(+) T-cell anergy are immune escape mechanisms of clear cell renal cell carcinoma. Oncoimmunology 2012; 1: 1451-3.
3. Li C, Liu B, Dai Z, et al. Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther 2011; 12: 872-80.
4. Rivet J, Mourah S, Murata H, et al. VEGF and VEGFR-1 are coexpressed by epithelial and stromal cells of renal cell carcinoma. Cancer 2008; 112: 433-42.
5. Kaplan RN, Riba RD, Zacharoulis S, et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premetastatic niche. Nature 2005; 438: 820-7.
6. Pantuck AJ, Thomas G, Belldegrun AS, et al. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications. Semin Oncol 2006; 33: 607-13.
7. Santoni M, Rizzo M, Burattini L, et al. Present and future of tyrosine kinase inhibitors in renal cell carcinoma: analysis of hematologic toxicity. Recent Pat Antiinfect Drug Discov 2012; 7: 104-10.
8. Powell JD, Pollizzi KN, Heikamp EB, et al. Regulation of immune responses by mTOR. Annu Rev Immunol 2012; 30: 39-68.
9. Pessina A, Albella B, Bueren J, et al. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 2001; 6: 729-40.
10. Kumar R, Crouthamel M-C, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009; 101: 1717-23.
11. Mantovani A, Cassatella MA, Costantini C, et al. Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol 2011; 11: 519-31.
12. Lõpez-Lago MA, Posner S, Thodima VJ, et al. Neutrophil chemokines secreted by tumor cells mount a lung antimetastatic response during renal cell carcinoma progression. Oncogene 2013;32: 1752-60.
13. He S, Lamers GE, Beenakker JW, et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model. J Pathol 2012; 227: 431-45.
14. Jensen HK, Donskov F, Marcussen N, et al. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol 2009; 27: 4709-17.
15. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor- targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-9.
16. Patil S, Figlin RA, Hutson TE, et al. Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma. Ann Oncol 2011; 22: 295-300.
17. Ohno Y, Nakashima J, Ohori M, et al. Pretreatment neutrophil-to- lymphocyte ratio as an independent predictor of recurrence in patients with nonmetastatic renal cell carcinoma. J Urol 2010; 184: 873-8.
18. Ohno Y, Nakashima J, Ohori M, et al. Followup of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol 2012; 187: 411-17.
19. Keizman D, Ish-Shalom M, Huang P, et al. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma. Eur J Cancer 2012; 48: 202-8.
20. Pichler M, Hutterer GC, Stoeckigt C, et al. Validation of the pre-treatment neutrophil-lymphocyte ratio as a prognostic factor in a large European cohort of renal cell carcinoma patients. Br J Cancer 2013; 108: 901-7.
21. Santoni M, De Giorgi U, Iacovelli R, et al. Pre-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer 2013; 109: 1755-59.
22. Hemmerlein B, Markus A, Wehner M, et al. Expression of acute and late-stage inflammatory antigens, c-fms, CSF-1, and human monocytic serine esterase 1, in tumor-associated macrophages of renal cell carcinomas. Cancer Immunol Immunother 2000; 49: 485-92.
23. Perez-Gracia JL, Prior C, Guillén-Grima F, et al. Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array. Br J Cancer 2009; 101: 1876-83.
24. Toge H, Inagaki T, Kojimoto Y, et al. Angiogenesis in renal cell carcinoma: the role of tumor-associated macrophages. Int J Urol 2009; 16: 801-7.
25. Hemmerlein B, Scherbening J, Kugler A, et al. Expression of VCAM-1, ICAM-1, E- and P-selectin and tumour-associated macrophages in renal cell carcinoma. Histopathology 2000; 37: 78-83.
26. Daurkin I, Eruslanov E, Stoffs T, et al. Tumor-associated macrophages mediate immunosuppression in the renal cancer microenvironment by activating the 15-lipoxygenase-2 pathway. Cancer Res 2011; 71: 6400-9.
27. Lin JC, Liu CL, Lee JJ, et al. Sorafenib induces autophagy and suppresses activation of human macrophage. Int Immunopharmacol 2013; 15: 333-9.
28. Zhang W, Zhu XD, Sun HC, et al. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects. Clin Cancer Res 2010; 16: 3420-30.
29. 2 in murine macrophages. Int Immunopharmacol 2010; 10: 1220-8.
30. Ko JS, Rayman P, Ireland J, et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained. Cancer Res 2010; 70: 3526-36.
31. Sakaguchi S, Sakaguchi N, Shimizu J, et al. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol Rev 2001; 182: 18-32.
32. Finke J, Ko J, Rini B, et al. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. Int Immunopharmacol 2011; 11: 856-61.
33. Kobayashi M, Suzuki K, Yashi M, et al. Tumor infiltrating dendritic cells predict treatment response to immunotherapy in patients with metastatic renal cell carcinoma. Anticancer Res 2007; 27: 1137-41.
34. Cabillic F, Bouet-Toussaint F, Toutirais O, et al. Interleukin-6 and vascular endothelial growth factor release by renal cell carcinoma cells impedes lymphocyte-dendritic cell cross-talk. Clin Exp Immunol 2006; 146: 518-23.
35. Hipp MM, Hilf N, Walter S, et al. Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses. Blood 2008; 111: 5610-20.
36. Alfaro C, Suarez N, Gonzalez A, et al. Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 2009; 100: 1111-19.
37. Eckl J, Buchner A, Prinz PU, et al. Transcript signature predicts tissue NK cell content and defines renal cell carcinoma subgroups independent of TNM staging. J Mol Med 2012; 90: 55-66.
38. Margolin KA,. Interleukin-2 in the treatment of renal cancer. Semin Oncol 2000; 27: 194-203.
39. Krusch M, Salih J, Schlicke M, et al. The kinase inhibitors sunitinib and sorafenib differentially affect NK cell antitumor reactivity in vitro. J Immunol 2009; 183: 8286-94.
40. Huang Y, Wang Y, Li Y, et al. Role of sorafenib and sunitinib in the induction of expressions of NKG2D ligands in nasopharyngeal carcinoma with high expression of ABCG2. J Cancer Res Clin Oncol 2011; 137: 829-37.
41. Kopecký O, Lukesová S, Vroblová V, et al. Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma. Acta Med 2007; 50: 207-12.
42. Oldham KA, Parsonage G, Bhatt RI, et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol 2012; 61: 385-94.
43. Wehler TC, Graf C, Altherr K, et al. SDF1β expression in renal cell carcinoma correlates with grading and infiltration by CD8+ T-cells. Anticancer Res 2011; 31: 2797-803.
44. Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res 2008; 14: 6674-82.
45. Ning H, Shao QQ, Ding KJ, et al. Tumor-infiltrating regulatory T cells are positively correlated with angiogenic status in renal cell carcinoma. Chin Med J (Engl) 2012; 125: 2120-5.
46. Chiou SH, Sheu BC, Chang WC, et al. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol 2005; 67: 35-50.
47. Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002; 8: 793-800.
48. Drake CG, McDermott DF, Sznol M, et al. Survival, safety, and response duration results of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in a phase I trial in patients with previously treated metastatic renal cell carcinoma (mRCC): long-term patient follow-up. J Clin Oncol 2013; 31:abstr 4514.
49. Cho DC, Sosman JA, Sznol M, et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2013; 31:abstr 4505.
50. Zhao W, Gu YH, Song R, et al. Sorafenib inhibits activation of human peripheral blood T cells by targeting LCK phosphorylation. Leukemia 2008; 22: 1226-33.
51. Gu Y, Zhao W, Meng F, et al. Sunitinib impairs the proliferation and function of human peripheral T cell and prevents T-cell-mediated immune response in mice. Clin Immunol 2010; 135: 55-62.
52. Breslin EM, White PC, Shore AM, et al. LY294002 and rapamycin co-operate to inhibit T-cell proliferation. Br J Pharmacol 2005; 144: 791-800.
53. Powles T, Chowdhury S, Bower M, et al. The effect of sunitinib on immune subsets in metastatic clear cell renal cancer. Urol Int 2011; 86: 53-9.
54. Adotevi O, Pere H, Ravel P, et al. A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patients. J Immunother 2010; 33: 991-8.
55. Desar IM, Jacobs JH, Hulsbergen-vandeKaa CA, et al. Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. Int J Cancer 2011; 129: 507-12.
56. Huijts CM, Santegoets SJ, van den Eertwegh AJ, et al. Phase I-II study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell cancer. BMC Cancer 2011; 11: 505.